<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01923675</url>
  </required_header>
  <id_info>
    <org_study_id>R01EY0021242</org_study_id>
    <nct_id>NCT01923675</nct_id>
  </id_info>
  <brief_title>Myopia:the Role of Cone Opsin Mutations &amp; Glasses That Control Axial Elongation</brief_title>
  <official_title>Myopia:the Role of Cone Opsin Mutations &amp; Glasses That Control Axial Elongation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To determine the effect of spectacles with a red blocking filter on myopia progression
           in children.

        2. To determine the effect of spectacles with a holographic diffuser that spreads incident
           light rays over an angle of 0.5 degrees on myopia progression in children

        3. To determine the combined effects of spectacles with a red blocking filter and a
           diffuser that spreads incident light over an angle of 0.5 degrees on myopia progression
           in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical trial we will determine whether commercially available lens tints that are
      normally used for cosmetic purposes or for blocking sunlight have a beneficial effect of
      slowing axial eye growth in children with myopia when used alone or in conjunction with a
      holographic diffuser that blurs the image slightly.

      The following procedures will be performed on a total of 240 children from 8 to 13 years of
      age:

        1. Color vision tests (Richmond Hardy-Rand-Rittler pseudoisochromatic plate test and/or the
           Rayleigh match test and/or the Neitz Test of Color Vision), and machine-based vision
           tests using the Titmus tester (color vision, binocularity, acuity, and heterophoria
           tests);

        2. each subject will provide a blood sample or a buccal swab for genetic analysis of the
           long and middle wavelength cone photopigment genes in order to determine the
           relationship between the cone opsins and myopia;

        3. eye measurements including axial length and corneal curvature will be performed using
           the Zeiss Intraocular Lens Master;

        4. cycloplegic autorefraction will be doe at the beginning of the study before participants
           start wearing the study spectacles, after 18 months if wearing the study spectacles, and
           6 months after participants stop wearing the study spectacles.

      4) subjects will be randomly assigned to one of four groups, consisting of 60 subjects each,
      each group will be assigned one of four study spectacles.

      The study spectacles for all participants will have the optimal lens corrections for both
      eyes.

      Group 1 participants will wear spectacles with lenses tinted to blocks red light.

      Group 2 participants will wear spectacles with lenses that have a holographic diffuser on
      surface of and that are tinted to reduce the light intensity by the same amount that the
      red-blocking tint does.

      Group 3 participants will wear spectacles that are tinted to block red light and that have a
      holographic diffuser.

      Group 4 participants will wear spectacles that are tinted to reduces the light intensity by
      the same amount that the red-blocking tint does.

      Participants will wear the study glasses for 18 months. Axial length measurements will be
      taken twice prior to when subjects begin wearing the glasses and once every three month
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myopia progression measured by rate of axial elongation of the eye</measure>
    <time_frame>every 3 months for 18 months</time_frame>
    <description>The axial length of both eyes will be measured before wearing the experimental eyeglasses, then once every three months thereafter for 18 months, and again 6 months after subjects stop wearing the study eye glasses. The rate of axial elongation will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myopia progression measured by cycloplegic autorefraction.</measure>
    <time_frame>18 months</time_frame>
    <description>A cycloplegic autorefraction will be done at the beginning of the study before subjects start wearing the study glasses, after 18 months of wearing the study glasses,and again about 6 months after wearing the study glasses stopped.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Group 1 block red light</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spectacles with red-blocking tint.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 blur image</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spectacles with holographic diffuser and color neutral tint</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 blur image and block red light</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spectacles with holographic diffuser and red-blocking tint.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 neutral tint</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Spectacles with color neutral tint</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spectacles with red-blocking tint</intervention_name>
    <description>Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.</description>
    <arm_group_label>Group 1 block red light</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spectacles with holographic diffuser and color neutral tint</intervention_name>
    <description>Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.</description>
    <arm_group_label>Group 2 blur image</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spectacles with holographic diffuser and red-blocking tint</intervention_name>
    <description>Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.</description>
    <arm_group_label>Group 3 blur image and block red light</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spectacles with color neutral tint</intervention_name>
    <description>Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.</description>
    <arm_group_label>Group 4 neutral tint</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nearsighted having a refractive error of at least -0.5 diopters

          -  myopia progression at least -.50 D per year in previous year

          -  astigmatism and anisometropia not more than 1.5 D

          -  distance monocular acuity 6/6 or better

          -  near monocular acuity of 0.4 M or better

          -  stereoacuity not more than 40 sec of arc at 40 cm

          -  able to respond to subjective testing

          -  no contact lens use during the study

          -  able to comply with wearing the experimental lenses daily for 18 months

          -  able to have axial length measurements accurately on the Zeiss Intraocular Lens Master

          -  willing to donate a blood sample or a buccal swab for genetic analysis

          -  can be refracted to 20/20 or 20/15

        Exclusion Criteria:

          -  glaucoma, amblyopia, strabismus

          -  ocular disease

          -  developmental delay

          -  history of wearing bifocal lenses

          -  any type of eye surgery

          -  color vision deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Neitz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jay Neitz, PhD</last_name>
    <phone>206 543 8065</phone>
    <email>jneitz@uw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maureen Neitz, PhD</last_name>
    <phone>206 543 7998</phone>
    <email>mneitz@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jay Neitz, PhD</last_name>
      <phone>206-543-8065</phone>
      <email>jneitz@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maureen Neitz, PhD</last_name>
      <phone>206 543 7988</phone>
      <email>mneitz@uw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jay Neitz, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maureen Neitz, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Carkeet A, Saw SM, Gazzard G, Tang W, Tan DT. Repeatability of IOLMaster biometry in children. Optom Vis Sci. 2004 Nov;81(11):829-34.</citation>
    <PMID>15545808</PMID>
  </reference>
  <reference>
    <citation>Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA. 2003 Oct 15;290(15):2057-60. Review.</citation>
    <PMID>14559961</PMID>
  </reference>
  <reference>
    <citation>Grosvenor T. Why is there an epidemic of myopia? Clin Exp Optom. 2003 Sep;86(5):273-5. Review.</citation>
    <PMID>14558848</PMID>
  </reference>
  <reference>
    <citation>Gwiazda J, Hyman L, Hussein M, Everett D, Norton TT, Kurtz D, Leske MC, Manny R, Marsh-Tootle W, Scheiman M. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1492-500.</citation>
    <PMID>12657584</PMID>
  </reference>
  <reference>
    <citation>Ip JM, Rose KA, Morgan IG, Burlutsky G, Mitchell P. Myopia and the urban environment: findings in a sample of 12-year-old Australian school children. Invest Ophthalmol Vis Sci. 2008 Sep;49(9):3858-63. doi: 10.1167/iovs.07-1451. Epub 2008 May 9.</citation>
    <PMID>18469186</PMID>
  </reference>
  <reference>
    <citation>Rein DB, Zhang P, Wirth KE, Lee PP, Hoerger TJ, McCall N, Klein R, Tielsch JM, Vijan S, Saaddine J. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006 Dec;124(12):1754-60. Erratum in: Arch Ophthalmol. 2007 Sep;125(9):1304.</citation>
    <PMID>17159036</PMID>
  </reference>
  <reference>
    <citation>Saw SM, Gazzard G, Shih-Yen EC, Chua WH. Myopia and associated pathological complications. Ophthalmic Physiol Opt. 2005 Sep;25(5):381-91. Review.</citation>
    <PMID>16101943</PMID>
  </reference>
  <reference>
    <citation>Saw SM, Katz J, Schein OD, Chew SJ, Chan TK. Epidemiology of myopia. Epidemiol Rev. 1996;18(2):175-87. Review.</citation>
    <PMID>9021311</PMID>
  </reference>
  <reference>
    <citation>Vitale S, Sperduto RD, Ferris FL 3rd. Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol. 2009 Dec;127(12):1632-9. doi: 10.1001/archophthalmol.2009.303.</citation>
    <PMID>20008719</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2013</study_first_posted>
  <last_update_submitted>August 13, 2013</last_update_submitted>
  <last_update_submitted_qc>August 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Jay Neitz</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>myopia</keyword>
  <keyword>nearsightedness</keyword>
  <keyword>axial elongation of the eye</keyword>
  <keyword>refractive error</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

